gb261
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2021 (NCT04923048)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD20BINDING AGENT
MS4A1 binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07159009 | Early Phase 1 (Phase 1) | Sep 4, 2025 | Jiao Tong University |
| NCT06945068 | Phase 1 | Jun 30, 2025 | Huazhong University of Science and Technology |
| NCT04923048 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2021 | Genor BioPharma Co., Ltd., Peninsula & South Eastern Haematology & Oncology Group |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genor BioPharma Co., Ltd. | For profit | 1 | 1 | 1 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peninsula & South Eastern Haematology & Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1